Validation of the Barcelona-MRI predictive model when PI-RADS v2.1 is used with trans-perineal prostate biopsies
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Morote, Juan
- dc.contributor.author Paesano, Nahuel
- dc.contributor.author Picola, Natàlia
- dc.contributor.author Muñoz-Rodríguez, Jesús
- dc.contributor.author Ruiz Plazas, Xavier
- dc.contributor.author Muñoz-Rivero, Marta V.
- dc.contributor.author Celma, Anna
- dc.contributor.author García de Manuel, Gemma
- dc.contributor.author Miró, Berta
- dc.contributor.author Servian, Pol
- dc.contributor.author Abascal-Junquera, José María
- dc.date.accessioned 2025-06-03T06:11:03Z
- dc.date.available 2025-06-03T06:11:03Z
- dc.date.issued 2024
- dc.description.abstract Purpose: To validate the Barcelona magnetic resonance imaging predictive model (BCN-MRI PM) in men with pre-biopsy multiparametric MRI (mpMRI) reported with the Prostate Imaging Reporting and Data System (PI-RADS) v2.1, followed by transrectal and transperineal prostate biopsies. Materials and methods: Prospective analysis of 3,264 men with PSA >3.0 ng/mL and/or abnormal digital rectal examination who were referred to ten participant centers in the csPCa early detection program of Catalonia (Spain), between 2021 and 2023. MpMRI was reported with the PI-RADS v2.1, and 2- to 4-core MRI-transrectal ultrasound (TRUS) fusion-targeted biopsy of suspected lesions and/or 12-core systematic biopsy were conducted. 2,295 (70.3%) individuals were referred to six centers for transrectal prostate biopsies, while 969 (39.7%) were referred to four centers for transperineal prostate biopsies. CsPCa was classified whenever the International Society of Urologic Pathology grade group was 2 or higher. Results: CsPCa was detected in 41% of transrectal prostate biopsies and in 45.9% of transperineal prostate biopsies (p < 0.016). Both BCN-MRI PM calibration curves were within the ideal correlation between predicted and observed csPCa. Areas under the curve and 95% confidence intervals were 0.847 (0.830-0.857) and 0.830 (0.823-0.855), respectively (p = 0.346). Specificities corresponding to 95% sensitivity were 37.6 and 36.8%, respectively (p = 0.387). The Net benefit of the BCN-MRI PM was similar with both biopsy methods. Conclusions: The BCN-MRI PM has been successfully validated when mpMRI was reported with the PI-RADS v2.1 and prostate biopsies were conducted via the transrectal and transperineal route.
- dc.format.mimetype application/pdf
- dc.identifier.citation Morote J, Paesano N, Picola N, Muñoz-Rodriguez J, Ruiz-Plazas X, Muñoz-Rivero MV, et al. Validation of the Barcelona-MRI predictive model when PI-RADS v2.1 is used with trans-perineal prostate biopsies. Int Braz J Urol. 2024 Sep-Oct;50(5):595-604. DOI: 10.1590/S1677-5538.IBJU.2024.0204
- dc.identifier.doi http://dx.doi.org/10.1590/S1677-5538.IBJU.2024.0204
- dc.identifier.issn 1677-5538
- dc.identifier.uri http://hdl.handle.net/10230/70594
- dc.language.iso eng
- dc.publisher Sociedade Brasileira de Urologia
- dc.relation.ispartof Int Braz J Urol. 2024 Sep-Oct;50(5):595-604
- dc.rights This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by/4.0/
- dc.subject.keyword Diagnosis
- dc.subject.keyword Magnetic resonance imaging
- dc.subject.keyword Prostatic neoplasms
- dc.title Validation of the Barcelona-MRI predictive model when PI-RADS v2.1 is used with trans-perineal prostate biopsies
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion